26 results
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
9 Jan 24
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
8:11am
at the 2023 American Society of Clinical Oncology (“ASCO”) Annual Meeting and the 2023 AACR Special Conference on Pancreatic Cancer.
“When tumor DNA
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
9 Nov 23
Results of Operations and Financial Condition
4:41pm
antigens were observed in 90% of immune responders presented at the Society for Immunotherapy of Cancer Anticipate initiating ELI-002 7P randomized Phase … to 3.9 months in above versus below median T cell responders (HR 0.14; 95% CI 0.03-0.61; p = 0.013). Presented at the Society for Immunotherapy
8-K
EX-99.1
jzpx11ch z58xnnho0qn
3 Nov 23
Other Events
5:10pm
8-K
EX-99.1
d9z 52l3jtryeo0h7
11 Aug 23
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides
11:42am
8-K
EX-99.1
j1wd 19za57
5 Jun 23
Other Events
8:00am
8-K
95r5t2mn7xcbpav
5 Jun 23
Other Events
8:00am
8-K
EX-99.3
n0x 8xw27
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
8-K
56teo18
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
8-K
EX-99.2
2o9j 9hpsvaoah9vw48r
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
8-K
EX-99.1
20qkt7l2l9aohp69
1 May 23
Other Events
4:14pm
8-K
827tcxndp3osfseyvq
1 May 23
Other Events
4:14pm
8-K
EX-99.1
81jpbz4x09em
27 Apr 23
Other Events
5:20pm
DEF 14A
9tpsr 9gt2wh7ka
27 Apr 22
Definitive proxy
4:04pm
8-K
EX-99.1
6zkz9s x6yk6ho9
30 Mar 22
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
4:52pm
10-K
55jzu9sq1sids8qi0
30 Mar 21
Annual report
5:00pm